Avid Bioservices Inc (CDMO)

[biopharm]

..Published July 31, 2019 and Dr Rolf Brekken with several researchers that worked with the late Dr Phil Thorpe etc etc and why? Not a mere mention of Oncologie Inc on this PS Targeting research so why no mention?

Is Oncologie Inc all truthful?

Is John Springs Stafford all truthful?

Is PS Targeting alive and well? Hell yes.. Dr Stopek took the money and ran it seems as she moved on after silencing the PS Targeting data as much and long as possible ...

For those that don't know IDEXX has presence in Maine / Missouri and worked with the late Dr Phil Thorpe

____


Authors Liang Y, Besch-Williford C, Cook MT, Belenchia A, Brekken RA, Hyder SM

Received 14 March 2019

Accepted for publication
18 July 2019

Published
31 July 2019

Volume 2019:11 Pages 249â??259

DOI https://doi.org/10.2147/BCTT.S208706

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Melinda Thomas

Peer reviewer comments 4

Editor who approved publication: Professor Pranela Rameshwar

APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice

Yayun Liang,1
Cynthia Besch-Williford,2
Matthew T Cook,3
Anthony Belenchia,4
Rolf A Brekken,5
Salman M Hyder1

1Department of Biomedical Sciences and Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, USA;

2IDEXX BioAnalytics, Columbia, MO, USA;

3Department of Biology, Washburn University, Topeka, KS, USA;

4Department of Nutrition and Exercise Physiology and Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, USA;

5Hamon Center for Therapeutic Oncology Research and Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA

Conclusion
In conclusion, our study provides a strong rationale for using a therapy regimen that combines APR-246 and 2aG4 to treat and prevent metastatic breast cancer in lungs originating from mtp53-expressing TNBC cells. The former targets and activates mtp53, likely inducing apoptosis of metastatic cells, while the latter disrupts tumor blood vessels and may also activate an immune response in tissues. Our in vivo animal studies showed no signs of toxicity with any of the regimens tested, leading us to propose that such therapy could prove beneficial and safe for women with TNBC, who currently have few effective treatment options. Furthermore, because the p53 mutation is common in other types of cancer and angiogenesis is essential for the spread of all types of tumors,45,46 we contend that our findings support further study of APR-246 and 2aG4 for treating human TNBC, as well as other forms of cancer.47,48

https://www.dovepress.com/apr-246-alone-and-in-combination-with-a-phosphatidylserine-targeting-a-peer-reviewed-fulltext-article-BCTT